Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 14/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 12/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 4/20 | 0.37 |
| ▸ | NOS1 | P29475 | 4/20 | 0.37 |
| ▸ | NOS2 | P35228 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582620 | 0.97 | FEN1 (0.42) | FEN1ALOX5APPIM1PIM3PIM2 | |
| SCHEMBL6583994 | 0.94 | NOS3 (0.41) | FEN1ALOX5APPIM1PIM3PIM2 | |
| SCHEMBL958723 | 0.82 | NOS1 (0.53) | FEN1ALOX5APNOS3NOS1NOS2 | |
| SCHEMBL956120 | 0.80 | NOS1 (0.53) | NOS3NOS1NOS2 | |
| SCHEMBL7078300 | 0.78 | NOS1 (0.38) | FEN1ALOX5APNOS3NOS1NOS2 | |
| SCHEMBL6587036 | 0.77 | TYR (0.37) | FEN1ALOX5APPIM1PIM3PIM2 | |
| SCHEMBL958697 | 0.77 | NOS1 (0.57) | NOS3NOS1NOS2 | |
| SCHEMBL7072944 | 0.75 | FEN1 (0.37) | FEN1ALOX5AP | |
| SCHEMBL6583572 | 0.75 | TYR (0.37) | FEN1PIM1PIM3PIM2 | |
| SCHEMBL419243 | 0.74 | MEN1 (0.39) | FEN1ALOX5APNOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1617743-A | New pharmaceutical combinations for nos inhibitors | PFIZER PROD INC (US) | 2005-05-18 | — | — | CN | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| CN-1617743-A | New pharmaceutical combinations for nos inhibitors | PFIZER PROD INC (US) | 2005-05-18 | — | — | CN | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| CN-1523015-A | 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines | �Ʒ� | 2004-08-25 | — | — | CN | disclosed |
| CN-1515554-A | Intermediate compound for producing 2-amino-6-(2-substituted-4-phenoxy) substituted pyridine compound | �Ʒ� | 2004-07-28 | — | — | CN | disclosed |
| EP-0958282-B1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PROD INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | PFIZER INC. | 2001-07-12 | — | — | US | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| CN-1246848-A | 2-amino-6- (2-substituted-4-phenoxy) -substituted pyridines | PFIZER PROD INC (US) | 2000-03-08 | — | — | CN | disclosed |
| EP-0958282-A1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | Pfizer Products Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998034919-A1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PRODUCTS INC. (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | FEN1 3241/4885ALOX5AP 1670/4885PIM1 4297/4885 |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | NOS1, PTGS1, NOS2 | FEN1 3816/4885ALOX5AP 251/4885PIM1 1108/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | FEN1 2988/4885ALOX5AP 3297/4885PIM1 3167/4885 |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | GRIN2C, GRIN2A, CNR2 | FEN1 4809/4885ALOX5AP 1604/4885PIM1 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.